European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017)

Hellings, Peter W.; Borrelli, D.; Pietikäinen, Sirpa; Agache, Ioana; Akdiş, Cezmi A.; Bachert, Claus; Bewick, M.; Botjes, Erna; Constantinidis, Jannis; Fokkens, Wytske J.; Haahtela, Tari; Hopkins, Claire; Illario, Maddalena; Joos, Guy; Lund, Valerie J.; Muraro, Antonella; Pugin, Benoı̂t; Seys, Sven; Somekh, David; Stjärne, Pär; Valiulis, Arūnas; Valovirta, Erkka; Bousquet, Jean

doi:10.1186/s13601-017-0186-3

Cited by 60 publications

(59 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases (March 29, 2017), 81 and a European symposium on the awareness of allergy (April 26-28, 2016). 82 The digital transformation of health and care for allergic diseases is rapidly becoming a reality.…”

Section: P Oliti C Al Ag Endamentioning

confidence: 99%

Food and drug allergy, and anaphylaxis in EAACI journals (2018)

Eigenmann

Akdiş²,

Bousquet

et al. 2019

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: "Allergy," "Pediatric Allergy and Immunology (PAI)," and "Clinical and Translational Allergy (CTA)." One of the major goals of EAACI is to support health promotion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. This paper summarizes the achievements of 2018 in anaphylaxis, and food and drug allergy. Main topics that have been focused are anaphylaxis, mechanisms of food allergy (FA), epidemiology of FA, food allergens, diagnosis of FA, prevention and control of FA, FA immunotherapy, drug allergy, and political agenda. K E Y W O R D S allergy, anaphylaxis, Clinical and Translational Allergy, drug allergy, European Academy of Allergy and Clinical Immunology, food allergy, hypersensitivity, Pediatric Allergy and Immunology

show abstract

Section: P Oliti C Al Ag Endamentioning

confidence: 99%

Food and drug allergy, and anaphylaxis in EAACI journals (2018)

Eigenmann

Akdiş²,

Bousquet

et al. 2019

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Medical mobile apps are expected to benefit not only researchers in providing real‐life data, but affect all stakeholders in health care in many ways, as is shown in Figure . From the patients’ perspective, mHealth technologies have the potential to involve patients as active partners in the management of their disease and as such increase the level of patient empowerment . Such shared and informed decision making requires access to easily understandable information about the disease and treatment options for which digital tools are well placed .…”

Section: Introductionmentioning

confidence: 99%

Mobile health tools for the management of chronic respiratory diseases

Sleurs

Seys

Bousquet

et al. 2019

Allergy

Self Cite

View full text Add to dashboard Cite

Background: The market of mobile health (mHealth) technology is rapidly evolving, making new mobile technologies potentially available for healthcare systems. Patient empowerment through self-monitoring of symptoms, shared decision making with the physician, and easily accessible education are important features extending the reach of mHealth technology beyond traditional care.Methods: Two digital distribution platforms (Apple App Store and Google Play Store) were searched for currently available mobile applications (apps) for patients with chronic respiratory diseases (CRDs). A new index (score ranging from 0 to 10) was developed to assess the potential of apps as a tool to empower patients through mobile technology (based on self-monitoring, personalized feedback, and patient education app features). Results:One hundred and twelve apps were retained for analysis and could be classified in 5 categories: Asthma (n = 71), COPD (n = 15), Asthma and COPD (n = 15), Rhinitis and Asthma (n = 5), and Rhinosinusitis (n = 6). Eighty percent were developed by medical technology companies compared to 18% by medical doctors and 2% by pharmaceutical companies. Two-thirds of apps allow disease self-monitoring, whereas over half of apps provide patient feedback through graphs. Sixty percent of apps contain easily accessible patient education material.Only three percent of apps reach a score of ≥7 on the newly designed patient empowerment index. Conclusions:A variety of apps are available for patients with CRDs of which only few were developed by or jointly with medical doctors. The majority of these apps include self-monitoring tools, but only few also provide personalized feedback, which is needed to adopt these apps into daily care. K E Y W O R D Sallergic rhinitis, asthma, chronic rhinosinusitis, mobile application, patient empowerment Sleurs and Seys shared first authors.Sleurs and Seys equally contributed to the manuscript.

show abstract

“…It is an important tool for precision medicine. 9,10 Within the AR CDSS, the VAS is used to assess AR control and to assist in making management decisions, assisting patients and healthcare providers to jointly determine AR treatment and its step-up or step-down strategy depending on the status of AR control. 2 The next step is to integrate the AR CDSS into an app for providers called Allergy Diary Companion, by producing an electronic version of it (e-CDSS).…”

Section: Introductionmentioning

confidence: 99%